<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

In Vivo and In Vitro Generation and Characterisation of EGFR-TKI Resistance in Patient-Derived Xenograft (PDX) and Cell Line Derived Xenograft (CDX) Models of NSCLC with Activating EGFR Mutations

Most non-small cell lung cancer (NSCLC) patients that have activating mutations in the EGFR gene will respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva®) and Gefitinib (Iressa®).